Literature DB >> 26669750

New phenazine analogues from Streptomyces sp. IFM 11694 with TRAIL resistance-overcoming activities.

Mohamed S Abdelfattah1,2, Naoki Ishikawa1, Utpal K Karmakar1, Kazuki Yamaku1, Masami Ishibashi1.   

Abstract

Two new phenazine derivatives, aotaphenazine (1) and 5,10-dihydrophencomycin (2), were isolated from the ethyl acetate extract of Streptomyces sp. IFM 11694. In addition, the known 1-phenazinecarboxylic acid (3), phencomycin (4) and 1,6-phenazinedicarboxylic acid (5) were identified. The structures of the isolated compounds (1-5) were characterized by spectroscopic methods including NMR and mass spectrometry data. Compound 1 showed the ability to overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance at concentration of 12.5 μM. Aotaphenazine (1) enhanced the levels of apoptosis inducing proteins DR4, DR5, p53 and also decreased the levels of cell survival protein Bcl-2 in TRAIL-resistant human gastric adenocarcinoma (AGS) cells in a dose-dependent manner.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26669750     DOI： 10.1038/ja.2015.129

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  18 in total

1.  Izumiphenazines A-C: isolation and structure elucidation of phenazine derivatives from Streptomyces sp. IFM 11204.

Authors:  Mohamed S Abdelfattah; Toume Kazufumi; Masami Ishibashi
Journal:  J Nat Prod       Date:  2010-11-23       Impact factor: 4.050

2.  Endophenazines A-D, new phenazine antibiotics from the athropod associated endosymbiont Streptomyces anulatus II. Structure elucidation.

Authors:  Philipp Krastel; Axel Zeeck; Klaus Gebhardt; Hans-Peter Fiedler; Joachim Rheinheimer
Journal:  J Antibiot (Tokyo)       Date:  2002-09       Impact factor: 2.649

3.  Izumiphenazine D, a new phenazoquinoline N-oxide from Streptomyces sp. IFM 11204.

Authors:  Mohamed S Abdelfattah; Kazufumi Toume; Masami Ishibashi
Journal:  Chem Pharm Bull (Tokyo)       Date:  2011       Impact factor: 1.645

Review 4.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Authors:  R K Srivastava
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

5.  Isolation and structure elucidation of izuminosides A-C: a rare phenazine glycosides from Streptomyces sp. IFM 11260.

Authors:  Mohamed S Abdelfattah; Kazufumi Toume; Masami Ishibashi
Journal:  J Antibiot (Tokyo)       Date:  2011-02-09       Impact factor: 2.649

6.  Sesquiterpenes with TRAIL-resistance overcoming activity from Xanthium strumarium.

Authors:  Utpal K Karmakar; Naoki Ishikawa; Kazufumi Toume; Midori A Arai; Samir K Sadhu; Firoj Ahmed; Masami Ishibashi
Journal:  Bioorg Med Chem       Date:  2015-05-31       Impact factor: 3.641

7.  Yoropyrazone, a new naphthopyridazone alkaloid isolated from Streptomyces sp. IFM 11307 and evaluation of its TRAIL resistance-overcoming activity.

Authors:  Mohamed S Abdelfattah; Kazufumi Toume; Masami Ishibashi
Journal:  J Antibiot (Tokyo)       Date:  2012-02-22       Impact factor: 2.649

Review 8.  TRAIL as a target in anti-cancer therapy.

Authors:  Gen Sheng Wu
Journal:  Cancer Lett       Date:  2009-03-18       Impact factor: 8.679

9.  The fluorometric microculture cytotoxicity assay.

Authors:  Elin Lindhagen; Peter Nygren; Rolf Larsson
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

10.  Chromomycins A2 and A3 from marine actinomycetes with TRAIL resistance-overcoming and Wnt signal inhibitory activities.

Authors:  Kazufumi Toume; Kentaro Tsukahara; Hanako Ito; Midori A Arai; Masami Ishibashi
Journal:  Mar Drugs       Date:  2014-06-05       Impact factor: 5.118
View more
  2 in total

1.  Sharkquinone, a new ana-quinonoid tetracene derivative from marine-derived Streptomyces sp. EGY1 with TRAIL resistance-overcoming activity.

Authors:  Mohamed S Abdelfattah; Mohammed I Y Elmallah; Adal A Mohamed; Masami Ishibashi
Journal:  J Nat Med       Date:  2017-04-04       Impact factor: 2.343

2.  Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles.

Authors:  Anthony Prandina; Lars Herfindal; Sylvie Radix; Pål Rongved; Stein O Døskeland; Marc Le Borgne; Florent Perret
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.